The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
amgen's mariTide shows promise with up to 20 percent weight loss in trial
Amgen's experimental obesity drug, MariTide, demonstrated an average weight loss of up to 20% after one year in a mid-stage trial, with no observed plateau. The trial also explored various dosing regimens, including less frequent injections, as the company aims to compete in the growing obesity drug market. Despite promising results, Amgen's shares fell as the outcomes were at the lower end of expectations.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.